Biotinidase deficiency: a novel phenotype from a tertiary care centre

Ebin Roshan Paul; Davis Manuel; R. A. Shajahan; Jayalekshmi U.; Anjali Ann Chacko

doi:10.18203/2349-3291.ijcp20233961

Authors

Ebin Roshan Paul Department of Clinical Genetics, PK Das Institute of Medical Sciences, Ottapalam, Kerala, India
Davis Manuel Department of Neurology, PK Das Institute of Medical Sciences, Ottapalam, Kerala, India
R. A. Shajahan Department of Paediatrics, PK Das Institute of Medical Sciences, Ottapalam, Kerala, India
Jayalekshmi U. Department of Paediatrics, PK Das Institute of Medical Sciences, Ottapalam, Kerala, India
Anjali Ann Chacko Department of Paediatrics, PK Das Institute of Medical Sciences, Ottapalam, Kerala, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20233961

Keywords:

BD, Corneal opacity , Acute infract, Metabolic disorder

Abstract

Biotinidase deficiency (BD) (OMIM 609019) autosomal recessive inherited metabolic disorder where enzyme biotinidase, is defective and biotin is not recycled in body. One novel phenotype reported from our tertiary care centre, 3-month-old baby presented with bilateral corneal haziness, development delay and seizures. Evaluation showed metabolic acidosis, persistent lactate elevation and MRI showed acute infract. Metabolic evaluation showed profound BD, confirmed by molecular testing. Treatment and follow up with biotin showed clearing of corneal opacity, resolution of bleed and improvement in development and seizures. BD has got wide range of clinical manifestations- neurologic, dermatologic, ophthalmologic and immunological features. Acute infract and corneal opacity are not yet reported in OMIM literature and BD not considered in differential diagnosis of stroke in metabolic disorders. Being clinicians, it is our responsibility to add novel associations and clinical findings and thus broaden the phenotype.

Metrics

Metrics Loading ...

References

Chedrawi AK, Ali A, Al Hassnan ZN, Faiyaz-Ul-Haque M, Wolf B. Profound biotinidase deficiency in a child with predominantly spinal cord disease. J Child Neurol. 2008;23(9):1043-8.

Gompertz D, Draffan GH, Watts JL, Hull D. Biotin-responsive beta-methylcrotonylglycinuria. Lancet. 1971;2(7714):22-4.

Mardach R, Zempleni J, Wolf B, Cannon MJ, Jennings ML, Cress S et al. Biotin dependency due to a defect in biotin transport. J Clin Invest. 2002;109(12):1617-23.

Harper P. Practical genetic counselling, 5th edn. Butterworth- Heinmann, London. 1998.

Mumtaz HA, Gupta V, Singh P, Marwaha RK, Khandelwal N. MR imaging findings of glutaric aciduria type II Singapore Med J. 2010;51(4):e69-71.

Singh P, Gurnani R, Rawat A. Brain MRI findings in an infant with congenital biotinidase deficiency. BMJ Case Reports CP. 2021;14:e246167.

Ahmed S, Ni M, Deberardinis R, Habib A, Akbar F, Afroze B. Clinico-Pathological and Molecular Spectrum of Biotinidase Deficiency-Experience from a Lower Middle-Income Country. Clin Lab. 2021;67(6).

Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutation Taster 2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361-2.